HIGHLIGHTS
- who: Pauline Puylaert and collaborators from the Laboratory of Physiopharmacology, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Laboratory of Physiopharmacology, Faculty of Medicine and Health Sciences, University of Antwerp have published the Article: The Impact of RIPK1 Kinase Inhibition on Atherogenesis: A Genetic and a Pharmacological Approach, in the Journal: Biomedicines 2022, 10, x FOR PEER REVIEW of /2022/
- what: By administering GSK`547, the authors aimed to evaluate the drugability of RIPK1 kinase in ApoE-/- Fbn1C1039G+/- mice, which is a unique model of advanced human-like atherosclerosis . Although plaque formation was also observed in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.